Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8778546 | 0.98 | HRH3 (0.53) | ALDH3A1HRH3DRD4DRD2DRD3 | |
| SCHEMBL8778507 | 0.98 | HRH3 (0.53) | ALDH3A1HRH3DRD4DRD2DRD3 | |
| SCHEMBL8778548 | 0.98 | HRH3 (0.53) | ALDH3A1HRH3DRD4DRD2DRD3 | |
| SCHEMBL1043999 | 0.98 | HRH3 (0.53) | ALDH3A1HRH3DRD4DRD2DRD3 | |
| SCHEMBL8778528 | 0.98 | HRH3 (0.53) | ALDH3A1HRH3DRD4DRD2DRD3 | |
| SCHEMBL1077698 | 0.93 | DRD4 (0.52) | ALDH3A1HRH3DRD4DRD2DRD3 | |
| SCHEMBL9770302 | 0.89 | ALDH3A1 (0.62) | ALDH3A1HRH3DRD4DRD2DRD3 | |
| SCHEMBL712373 | 0.86 | DRD4 (0.48) | ALDH3A1HRH3DRD4DRD2DRD3 | |
| SCHEMBL30514014 | 0.86 | HRH3 (0.61) | ALDH3A1HRH3DRD4DRD2DRD3 | |
| SCHEMBL11815991 | 0.86 | HRH3 (0.61) | ALDH3A1HRH3DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| EP-1931425-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-0498188-B1 | Oximethers and fungicides containing them | BASF AG (DE) | 1996-03-27 | — | — | EP | disclosed |
| EP-0679636-A1 | Oximethers and fungicides containing them | BASF Aktiengesellschaft (DE) | 1995-11-02 | — | — | EP | disclosed |
| EP-0678505-A1 | Oximethers and fungicides containing them | BASF AKTIENGESELLSCHAFT (DE) | 1995-10-25 | — | — | EP | disclosed |
| US-5446067-A | For treatment of crops, seeds, soils | BASF AKTIENGESELLSCHAFT (DE) | 1995-08-29 | — | — | US | disclosed |
| EP-0498188-A2 | Oximethers and fungicides containing them | BASF Aktiengesellschaft (DE) | 1992-08-12 | — | — | EP | disclosed |
| US-5041618-A | α-arylacrylates and fungicides containing these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0348766-B1 | ALPHA-ARYLACRYLIC-ACID ESTERS AND FUNGICIDES CONTAINING SAME | BASF Aktiengesellschaft (DE) | 1991-04-17 | — | — | EP | disclosed |
| US-4942143-A | Imidazothiadiazine derivatives, and their use as medicaments | HOECHST JAPAN LIMITED (JP) | 1990-07-17 | — | — | US | disclosed |
| EP-0348766-A2 | Alpha-arylacrylic-acid esters and fungicides containing same | BASF Aktiengesellschaft (DE) | 1990-01-03 | — | — | EP | disclosed |
| EP-0286041-A1 | Imidazothiadiazine derivatives, a process for preparing the same and their use as medicaments | HOECHST JAPAN LIMITED (JP) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH3A1 1083/4885HRH3 866/4885DRD4 888/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH3A1 1083/4885HRH3 866/4885DRD4 888/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ALDH3A1 215/4885HRH3 538/4885DRD4 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.